FDA Drug recall D-0522-2020
Amiodarone Hydrochloride Injection, USP, 900 mg per 18 mL (50 mg / mL), 18 mL Multiple Dose Vial, Rx only, Distributed by AuroMedics Pharma…
- FDA Drug
- Class III
- terminated
- Published 2019-12-04
On 2019-12-04 the FDA classified a Class III recall of Amiodarone Hydrochloride Injection, USP, 900 mg per 18 mL (50 mg / mL), 18 mL Multiple Dose Vial, Rx only, Distributed by AuroMedics Pharma… by Auromedics Pharma, citing crystallization: Presence of visible particulate matter.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0522-2020 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2019-11-11 |
| Published | 2019-12-04 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Auromedics Pharma |
| Distribution | US |
Product
Amiodarone Hydrochloride Injection, USP, 900 mg per 18 mL (50 mg / mL), 18 mL Multiple Dose Vial, Rx only, Distributed by AuroMedics Pharma LLC E. Windsor, NJ. 08520, Made in India. NDC 55150-182-18
Reason
Crystallization: Presence of visible particulate matter.
Identifiers
| ndc | 55150-180-03 |
|---|---|
| ndc | 55150-181-09 |
| ndc | 55150-182-18 |
| code_info | Lot#: CAH180013, CAH180014, exp. date Jul 2020 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0522-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.